Vincamine ameliorates hepatic fibrosis via inhibiting S100A4‐mediated farnesoid X receptor activation: based on liver microenvironment and enterohepatic circulation dependence
British Journal of Pharmacology · 2025-06 · 182 (11) · 2447-2465
DOI: 10.1111/bph.17471 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 12.02.2025. Verfasst von Yu-Chen Jiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Traditional Chinese Korean Medicine Research (State Ethnic Affairs); College of Pharmacy, Yanbian University, Yanji, China. Hauptthemen laut MEDLINE: Receptors, Cytoplasmic and Nuclear, Liver Cirrhosis, S100 Calcium-Binding Protein A4. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jilin Province.
Abstract (Originalsprache)
Background and Purpose Vincamine has extensive biological and pharmaceutical activity. We examined the hepatoprotective effects and mechanisms by which vincamine suppresses hepatic fibrosis. Experimental Approach Hepatic stellate cells (HSCs), TGF‐ β stimulated, were cultured with either vincamine, farnesoid X receptor (NR1H4; FXR) agonist or antagonist. Further, C57BL/6 mice were given thioacetamide (TAA) to induce hepatic fibrosis and subsequently treated with vincamine or curcumin. Key Results Vincamine regulated the deposition of extracellular matrix (ECM), inflammatory factors and S100A4, and up‐regulated FXR and TGR5 (GPBA receptor) in activated HSCs, by activating FXR. FXR deficiency blocked vincamine effect on FXR, TGR5, α ‐smooth muscle actin ( α ‐SMA) and IL1R1 in activated LX‐2 cells. Vincamine corrected ECM imbalance, inflammatory secretion and FXR/TGR5 down‐regulation in activated LX‐2 cells with stimulating medium from LPS‐primed THP‐1 cells. S100A4 deficiency increased FXR and TGR5, and decreased IL‐1β expression in activated THP‐1. Further, S100A4 deficiency in activated macrophages could elevate FXR and TGR5 expression in activated LX‐2, strengthening the impact of vincamine on α ‐SMA and IL‐1β expression. Further, vincamine reduced serum ALT/AST levels, liver and intestinal histopathological changes, and caused ECM accumulation and protected the intestinal barrier in thioacetamide‐induced hepatic fibrosis mice. Vincamine decreased inflammatory factors e.g. caspase 1 and IL‐1β, and inhibited the S100A4‐mediated FXR‐TGR5 pathway. Conclusion and Implications Vincamine significantly reverses hepatic fibrosis via inhibiting S100A4 involved in the crosstalk between macrophages and HSCs, and by activating the FXR‐TGR5 pathway. Targeting the S100A4‐mediated FXR dependence on modulating the liver environment may be the key target of vincamine in inhibiting hepatic fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory for Traditional Chinese Korean Medicine Research (State Ethnic Affairs); College of Pharmacy, Yanbian University, Yanji, China.
- Jilin Vocational and Technical College, Longjing, China.
ORCID-Profile: Ji-Xing Nan
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jilin Province
Zitieren
APA
Jiang, Y. C., Guo, J., Liu, S. H., Dai, X., Wang, C. Y., Lian, L. H., Cui, Z. Y., Nan, J. X., & Wu, Y. L. (2025). Vincamine ameliorates hepatic fibrosis via inhibiting S100A4‐mediated farnesoid X receptor activation: based on liver microenvironment and enterohepatic circulation dependence. British Journal of Pharmacology, 182(11), 2447-2465. https://doi.org/10.1111/bph.17471
Vancouver
Jiang YC, Guo J, Liu SH, Dai X, Wang CY, Lian LH, et al. Vincamine ameliorates hepatic fibrosis via inhibiting S100A4‐mediated farnesoid X receptor activation: based on liver microenvironment and enterohepatic circulation dependence. British Journal of Pharmacology. 2025;182(11):2447-2465. doi:10.1111/bph.17471
BibTeX
@article{Jiang2025,
author = {Jiang, Yu-Chen and Guo, Jia and Liu, Sai-Hu and Dai, Xu and Wang, Chen-Yu and Lian, Li-Hua and Cui, Zhen-Yu and Nan, Ji-Xing and Wu, Yan-Ling},
title = {Vincamine ameliorates hepatic fibrosis via inhibiting S100A4‐mediated farnesoid X receptor activation: based on liver microenvironment and enterohepatic circulation dependence},
journal = {British Journal of Pharmacology},
year = {2025},
volume = {182},
number = {11},
pages = {2447--2465},
doi = {10.1111/bph.17471}
}
EUVIMED